OR WAIT null SECS
The company has announced plans to establish a commercial presence in six European countries.
Moderna is expanding its commercial presence in Europe to Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden, the company announced on Feb. 16, 2022. The expansion will support delivery of messenger RNA (mRNA) vaccines and therapies in Europe. Moderna currently has subsidiaries in Italy, France, Germany, Spain, Switzerland, and the United Kingdom. The company also announced an expansion in Asia on Feb. 15, 2022.
The company’s COVID-19 vaccine and booster are approved for use in Europe, and the European Commission has ordered 460 million doses. The company currently has manufacturing partnerships with Lonza in Switzerland and the Netherlands, ROVI in Spain, and Recipharm in France. The expansion is part of Modern’s scale up of the manufacturing and distribution of its COVID-19 vaccines and the advancement of other mRNA vaccines and therapeutics.
"Europe has played a critical role in Moderna's ability to manufacture and deliver our COVID-19 vaccine across the world, protecting millions of people from COVID-19 infection, hospitalization, and death. After a decade of pioneering the development of our mRNA platform, I am proud of the growth we continue to achieve," said Stéphane Bancel, Chief Executive Officer of Moderna, in a press release. "I look forward to furthering our collaborations with European researchers and partners to leverage our mRNA technology and expand treatment options to improve the lives of patients across Europe."